1. P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES. (23rd June 2022) Authors: Joffe, E.; Nowakowski, G.; Tun, H.; Rosenthal, A.; Lunning, M.; Ramchandren, R.; Li, C.-C.; Zhou, L.; Martinez, E.; von Roemeling, R.; Earhart, R.; McMahon, M.; Isufi, I.; Leslie, L. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1011 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗